



(19) Europäisches Patentamt
 European Patent Office
 Office européen des brevets



(11) Publication number:

0 196 222 B1

(12)

EUROPEAN PATENT SPECIFICATION

- (45) Date of publication of patent specification: **29.01.92** (51) Int. Cl. 5: **C07C 233/81, C07D 213/82, C07D 307/84, C07C 233/57, A61K 31/195, A61K 31/215**
 (21) Application number: **86302217.4**
 (22) Date of filing: **26.03.86**

(54) Hypoglycemic agent.

- (30) Priority: **27.03.85 JP 62276/85**
 (43) Date of publication of application:
01.10.86 Bulletin 86/40
 (45) Publication of the grant of the patent:
29.01.92 Bulletin 92/05
 (84) Designated Contracting States:
CH DE FR GB LI
 (56) References cited:
EP-A- 0 093 551
GB-A- 2 102 412

- (73) Proprietor: **AJINOMOTO CO., INC.**
5-8, Kyobashi 1-chome, Chuo-ku
Tokyo 104(JP)
 (72) Inventor: **Toyoshima, Shigeshi**
No. 3-14-22, Funabashi Setagaya-ku
Tokyo(JP)
 Inventor: **Seto, Yoshiko**
No. 1-2-3-406, Natsumidai
Funabashi-shi Chiba-ken(JP)
 Inventor: **Shinkai, Hisashi**
No. 1155-2, Nakamaruko Nakahara-ku
Kawasaki-shi Kanagawa-ken(JP)
 Inventor: **Toi, Koji**
No. 1642-100, Nagae Hayamamachi
Miura-gun Kanagawa-ken(JP)
 Inventor: **Kumashiro, Izumi**
No. 1071-17, Ichigao-cho Midori-ku
Yokohama-shi Kanagawa-ken(JP)

- (74) Representative: **Armitage, Ian Michael et al**
MEWBURN ELLIS & CO. 2/3 Cursitor Street
London EC4A 1BQ(GB)

EP 0 196 222 B1

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid (Art. 99(1) European patent convention).

Description

The present invention relates to hypoglycemic agents useful as antidiabetic drugs.


5 Background to the invention

Hitherto, as antidiabetic drugs for oral use, there have been widely employed sulfonyl urea which shows hypoglycemic action particularly through a promotion of the secretion of insulin, and a biguanide which shows a hypoglycemic action particularly through the metabolism of sugar. However, they are somewhat 10 unsatisfactory as to their side effects (see Textbook of Endocrinology 4th ed., 1968, p.719 (Saunders); Diabetes, 19, 785, 1970; Ann.Rev.Pharmacol., 15, 351, 1975).

No report has been found that a D-phenylalanine derivative possesses hypoglycemic action.


Summary of the invention and description of preferred embodiments

15 According to one aspect of the invention there is provided for pharmaceutical, particularly hypoglycemic, use, a D-phenylalanine derivative represented by the general formula:




25 or a salt thereof, or a precursor which can be converted thereto in the human or animal body. Such compounds can lower the value of blood sugar and thus can be used as an antidiabetic drug for an oral use as well as by injection.

Among the foregoing D-phenylalanine derivatives, those represented by the general formula:




and the salts thereof are novel.

In the above general formulae: R¹ is hydrogen, alkyl of 1 to 5 carbon atoms such as methyl, ethyl, n-40 propyl, isopropyl, n-butyl, and sec-butyl, aryl of 6 to 12 carbon atoms such as phenyl, tolyl, naphthyl, and



45 aralkyl of 6 to 12 carbon atoms such as benzyl,



-CH₂CO₂R³, -CH(CH₃)-OCO-R³, or -CH₂-OCO-C(CH₃)₃. R² is a group comprising aryl of 6 to 12 carbon atoms such as phenyl, naphthyl, and indanyl, a hetero six-membered ring such as quinolynyl, pyridyl, a hetero five-membered ring such as 2-benzofuranyl, cycloalkyl such as cyclohexyl and cyclopentyl, bicycloalkyl such as bicycloheptyl, and cycloalkenyl such as 1-cyclohexenyl, 2-cyclohexenyl, 3-cyclohexenyl, 1-cyclopentenyl and 2-cyclopentenyl, any of which groups optionally having one or more substituents;

R^3 is hydrogen or lower alkyl such as methyl, ethyl, isopropyl and pentyl; and R^4 stands for those R^2 groups which provide novel compounds hereof, notably phenyl which has one or more alkyl substituents of 2 to 5 carbon atoms, cyclohexyl which has one or more substituents, cyclopentyl, bicycloalkyl, cycloalkenyl, indanyl or 2-benzofuranyl, any of which may have one or more substituents. The foregoing definitions are 5 subject to the provisos: (i) that when R^1 and R^3 are both hydrogen then R^2 is other than substituted or unsubstituted phenyl or naphthyl; and (ii) that when R^1 and R^3 are both hydrogen then R^4 is other than substituted phenyl or cyclohexyl.

When an organic group in the above general formulae has a substituent, examples of such substituents include a halogen atom such as fluorine or chlorine, a hydroxyl group, a C_{1-5} alkyl group such as methyl, 10 ethyl, trichloromethyl, trifluoromethyl, propyl, isopropyl, n-butyl, sec-butyl, and tert-butyl, a C_{1-5} alkenyl group such as ethenyl, propenyl, and butenyl, an alkylidene group such as


75



and

20

25



a C_{1-5} alkoxy such as methoxy and ethoxy, a C_{1-5} alkyl group which has been substituted by such C_{1-5} alkoxy group such as methoxymethyl and 1-ethoxyethyl, a C_{1-5} alkylene group which has been substituted by such C_{1-5} alkoxy group in the same manner as above such as 1-methoxyethylene. In the 30 case of a bicycloalkyl group as stated above, it can include a bicycloheptyl or a derivative thereof such as bicyclo (2,2,1)heptyl.

In the case of the compound represented by the general formula (I) wherein R^1 stands for a hydrogen atom, it can be formed by conventional methods via the salts thereof with various cations such as an alkali metal, for example, sodium and potassium, an alkali earth metal, for example, calcium, an inorganic base, for example, ammonia, an organic base, for example, cyclohexylamine, N-methyl-D-glucosamine, or a basic 35 amino acid (lysine, arginine and the like).

The D-phenylalanine derivative as shown by the formula (I) mentioned above, can be prepared using conventional N-acylating reactions as in the Examples given below.

Most of the D-phenylalanine derivatives supplied by this invention are novel compounds which have not 40 been described yet in the literature.

The D-phenylalanine derivatives used in the present invention are useful as a hypoglycemic agent for treating diabetic mammals including humans. The derivatives can be used for lowering blood sugar by formulating them into a preparation such as tablets, capsules, and elixirs for oral administration and into an aseptic liquid preparation or an aseptic suspension preparation for parenteral administration such as 45 subcutaneous, intramuscular, intravenous injection, and suppositories. The D-phenylalanine derivatives in the present invention can be administered to a subject necessitating such treatment (animals and humans) in a dosage range of 0.1 to 1,000 mg per subject generally several times a day, that is, in a total daily dosage of 0.2 to 2,000 mg. The dosage varies according to the seriousness of disease, the body weight of subjects, and other factors acknowledged by those skilled in the art.

To produce the preparations using the D-phenylalanine derivatives as described above for the present 50 invention, they may be converted to dosage forms such as tablets, granules, powders, capsules, injections and suppositories by conventional methods.

For the production of oral preparations, there may be added to the D-phenylalanine derivative as the principal agent, adjuvants such as fillers, binders, disintegrators, lubricants, colors, and correctives, as 55 necessary, and then formed by conventional methods into tablets, coated tablets, granules, powders, capsules and the like.

Examples of specific materials which can be incorporated into tablets, capsules, and so forth are as follows: fillers such as cornstarch, lactose, white sugar, glucose, sorbitol, and crystalline cellulose; binders

such as polyvinyl alcohol, polyvinyl ether, ethyl cellulose, methyl cellulose, gum arabic, tragacanth gelatine, shellac, hydroxypropyl cellulose, hydroxypropyl starch, polyvinyl pyrrolidone; disintegrants such as starch, agar, gelatine powder, crystalline cellulose, calcium carbonate, sodium bicarbonate, calcium citrate, dextrin and pectin; lubricants such as magnesium stearate, talc, polyethylene glycol, silica, hardened plant oil; colors such as one which is allowed as an additive for the medicines; correctives such as cocoa powder, mentha herb, aromatic acid, mentha oil, borneol, cinnamon bark powder. These tablets and granules may be coated with sugar, gelatine, or the like, as desired.

For the production of the injectable formulations, there may be added to the D-phenylalanine derivative as the principal agent, a pH adjusting agent, a buffer agent, a stabilizing agent, preservatives or the like, as necessary to produce a material for subcutaneous, intramuscular or intravenous injection by conventional methods.

Examples

15 The present invention will be further explained in the following examples.

Example 1

N-(4-Ethylbenzoyl)-D-phenylalanine

20 D-Phenylalanine 2 g (12 mmole) was dissolved in 10% aqueous sodium hydroxide solution (10 ml), and acetone (10 ml) was added. An acetone (5 ml) solution of 4-ethyl benzoyl chloride (2.5 g, 15 mmole) and a 10% aqueous sodium hydroxide solution were added dropwise to the mixture obtained above while stirring and cooling with ice over 20 minutes, the reaction solution being maintained at pH 10. The reaction solution was returned to the room temperature, stirred for 3 hours, and made an acidic with a dilute hydrochloric acid solution to precipitate crystals. The crystals were filtered, washed with water and recrystallized from ethyl acetate to obtain N-(4-ethylbenzoyl)-D-phenylalanine (3.0 g, yield 83%).
m.p. 165.5-166 °C

30 Specific Rotation $[\alpha]_D^{23} + 4.4^\circ$ (C = 1, methanol)

Examples 2 to 11

For Examples 2 to 8, in the same manner as in Example 1, using the following starting materials, each compound of 50 mmole, the following product compounds were produced. The compounds in Examples 9 to 11 were already known, and therefore were produced in accordance with the following literature references:

Example 9: J.Amer.Chem.Soc., 73, 1644, 1951,

Example 10: Pol.J.Chem., 53, 2239, 1979, and

Example 11: J.Chromatogr., 264, 63, 1983.

40

45

50

55

Example No.	Starting Material	Product	Yield (%)	M.P. (°C)	Specific Rotation
2	D-phenylalanine	N-(4-tolyl)-D-phenylalanine	83	152-155	$[\alpha]_D^{28} +46.2^\circ$ (C=0.5, methanol)
3	"	N-(2-fluorobenzoyl)-D-phenylalanine	74	91.5-93.5	$[\alpha]_D^{19} -8.8^\circ$ (C=1, methanol)
4	"	N-(3-fluorobenzoyl)-D-phenylalanine	81	112.5-116	$[\alpha]_D^{22} +48.6^\circ$ (C=1, methanol)
5	"	N-(4-fluorobenzoyl)-D-phenylalanine	80	142-145	$[\alpha]_D^{28} +40.4^\circ$ (C=0.5, methanol)
6	"	N-(3-trifluoromethylbenzoyl)-D-phenylalanine	77	118-119	$[\alpha]_D^{28} +40.4^\circ$ (C=1, methanol)
7	"	N-(4-trifluoromethylbenzoyl)-D-phenylalanine	70	136-137.5	$[\alpha]_D^{28} +36.3^\circ$ (C=1, methanol)
8	"	N-(4-anisoyl)-D-phenylalanine	65	85-90	$[\alpha]_D^{20} +60.2^\circ$ (C=0.5, methanol)
9	"	N-benzoyl-D-phenylalanine	81		
10	"	N-nicotinoyl-D-phenylalanine	62		
11	"	N-(2-naphthoyl)-D-phenylalanine	83		

Example 1255 N-Cyclopentylcarbonyl-D-phenylalanine

Cyclopentane carboxylic acid (1.5 g, 13 mmole) was dissolved in chloroform (50 ml), and N-hydroxysuccinimide 1.7 g was added. N,N'-Dicyclohexylcarbodiimide (3.0 g) was gradually added to the

5 mixture as obtained above while stirring and cooling with ice, and the mixture was stirred for 1 hour at the same temperature. The mixture was further stirred for 7 hours at room temperature. Glacial acetic acid (2 ml) was added to the mixture, and stirred for 1 hour. The insoluble matter was removed by filtration. The filtrate was washed with saturated aqueous sodium bicarbonate solution (30 ml), 1N aqueous hydrochloric acid solution (30 ml), and water (30 ml), and dried over magnesium sulfate. The magnesium sulfate was removed by filtration, and the solution thus obtained was concentrated under reduced pressure to dryness. The matter was recrystallized from ethyl acetate to afford cyclopentane carboxylic acid N-hydroxysuccinimide ester (2.5 g, yield 91%).

10 The ester derivative thus obtained above (2.5 g), was dissolved in chloroform (20 ml). This solution was added to a chloroform solution (40 ml) of D-phenylalanine methyl ester hydrochloride (3.0 g, 14 mmole) and triethylamine (1.4 g), and the mixture thus obtained was stirred for 18 hours at room temperature. The reaction solution was washed with 1N aqueous hydrochloric acid solution (40 ml), saturated aqueous sodium bicarbonate solution (40 ml) and water (40 ml), and dried over magnesium sulfate. The magnesium sulfate was removed by filtration and the filtrate was concentrated under reduced pressure to dryness. The matter was recrystallized from ethyl acetate-n-hexane to afford N-cyclopentyl-carbonyl-D-phenylalanine methyl ester (3.0 g, yield 84%).

15 The methyl ester derivative (3.0 g) thus obtained above, was dissolved in methanol (10 ml), and 1N aqueous sodium hydroxide solution (20 ml) was added. The mixture was stirred for 30 minutes at room temperature and then made acidic with an addition of a dilute hydrochloric acid to precipitate crystals. The 20 crystals were filtered, washed with water, and recrystallized from methanol-water to give the desired product (2.7 g, yield 80%).

m.p. 108-110°C

Specific Rotation $[\alpha]_D^{22} -35.2^\circ$ (C = 0.5, methanol)

25 Examples 13 to 18

For Examples 13 to 16, in the same manner as in Example 12, using as the starting material the following compounds, each of 15 mmole, the following products were obtained. The compounds of Examples 17 and 18 stated in the above table were known, and therefore were produced in accordance with the following literature references:

30 Example 17: BEXXA BELG. NO. 893553, 48, 1981, and

Example 18: Bull.Chem.Soc.Jpn., 57, 2171, 1984.

35

40

45

50

55

Example No.	Starting Material	Product	Yield (%)	M.P. (°C)	Specific Rotation [α]D ²² (C=0.5, methanol)
13	2-benzofuran carboxylic acid	N-(2-benzofurylcarbonyl)-D-phenylalanine	59	114-116	+89.6°
14	5-indane carboxylic acid	N-(5-indanylcarbonyl)-D-phenylalanine	64	160-161	+52.0°
15	3-cyclohexene carboxylic acid	N-(3-cyclohexenylcarbonyl)-D-phenylalanine	62	100-101	-12.6°
16	bicyclo[2.2.1]-heptan-2-yl carboxylic acid	N-(bicyclo[2.2.1]heptan-2-ylcarbonyl)-D-phenylalanine	50	179-181	+33.4°
17	cyclohexene carboxylic acid	N-cyclohexylcarbonyl-D-phenylalanine	65		
18	benzoic acid	N-benzoyl-D-phenylalanine methyl ester	65		

Example 1955 N-(4-Isopropylcyclohexylcarbonyl)-D-phenylalanine

Platinum oxide (200 mg) as a catalyst was suspended in acetic acid (20 ml), and then (s)-(−)-perillic acid (2 g, 12 mmole) was added. The mixture thus obtained was stirred for 8 hours at room temperature under a

current of hydrogen gas. The catalyst was removed by filtration, and the filtrate was concentrated under reduced pressure to a dryness. The matter was recrystallized from methanol-water to obtain 4-isopropyl cyclohexane carboxylic acid (1.9 g, yield 93%).

After that, in the same manner as the reaction in Example 1, N-(4-isopropylcyclohexylcarbonyl)-D-phenylalanine was produced. It was crystallized from methanol-water to give the desired product (2.5 g, yield 61%).

m.p. 230-232°C

Specific Rotation $[\alpha]_D^{22} -28.2^\circ$ (C = 0.5, methanol)

Example 20

ICR-CDI mice (Male, five weeks old, Body weight: 20 g) which had been bred for one week, were abstained from food for 18 hours, and then used as test subjects.

The phenylalanine derivative of the present invention was suspended in 0.5% CMC-0.05 M tris-hydrochloride buffer (pH 7.4). The sample solution thus obtained was administered orally in fixed amounts to the test subjects. A predetermined time later, the percentage decrease in blood glucose with the comparison to the control group was determined. The results are shown in the following table.

20

Decrease in Blood Glucose (%)

	<u>Example No.</u>	<u>Amounts used (mg/kg)</u>	<u>60 Minutes</u>
25	1	25	34
	2	100	32
	3	"	24
30	4	"	24
	5	"	43
	6	250	37
35	7	100	33
	8	"	38
	9	"	34
40	10	250	19
	11	"	17
	12	50	22
45	13	100	31
	14	250	28
	15	100	28
50	16	250	16
	17	100	27
	18	250	37
55	19	25	50

Example 21N-Cumoyl-D-Phenylalanine

5 Cumic acid (15.0 g, 91 mmole) was dissolved in chloroform (150 ml), and N-hydroxysuccinimide (11.4 g, 99 mmole) was added thereto. N,N'-Dicyclohexylcarbodiimide (20.4 g, 99 mmole) was added gradually to the mixture obtained above while cooling with ice and stirring, and then the mixture thus obtained was returned to room temperature. The mixture was further stirred for 15 hours at room temperature. Glacial acetic acid (5 ml) was added thereto, and the mixture thus obtained was stirred and the insoluble matter
10 was removed by filtration. The filtrate was washed with saturated aqueous sodium bicarbonate (300 ml) and water (300 ml), and dried over magnesium sulfate. The magnesium sulfate was removed by filtration, and the filtrate thus obtained was concentrated under reduced pressure to dryness. The resultant substance was recrystallized from ethyl acetate to obtain cumic acid N-hydroxysuccinimide ester (18.8 g, yield 72 mmole).

15 The ester thus obtained above (18.8 g) was added to the chloroform solution (150 ml) of D-phenylalanine methyl ester hydrochloride (23.0 g, 110 mmole) and triethylamine (10.8 g, 110 mmole), and the mixture thus obtained was stirred for 15 hours at room temperature. The reaction solution was washed with 1N aqueous hydrochloric acid solution (300 ml), saturated aqueous sodium bicarbonate (300 ml) and water (300 ml), and dried over magnesium sulfate. The magnesium sulfate thus used was removed by filtration, and the filtrate thus obtained was concentrated under reduced pressure to dryness.

20 The residue thus obtained was recrystallized from ethyl acetate-n-hexane to obtain N-cumoyl-D-phenylalanine methyl ester (20.5 g, yield 69%).

25 The methyl ester thus obtained above (20.5 g) was dissolved in methanol (100 ml), and then 1N aqueous sodium hydroxide (100 ml) was added thereto. The mixture thus obtained was stirred for 10 minutes at room temperature, and was made acidic with an addition of diluted aqueous hydrochloric acid solution to precipitate crystals. The crystals were filtered, washed with water and recrystallized from methanol-water to give the desired product (18.1 g, yield 64%).

m.p. 177-178 °C

Specific Rotation $[\alpha]_D +25.5^\circ$ (C = 1, methanol)

30 Examples 22 to 30

In the same manner as in Example 21, using as the starting material the following compounds, each at 50 mmole, the following product compounds were produced.

35

40

45

50

55

Example No.	Starting Material	Product	Yield (%)	M.P. (°C)	Specific Rotation
22	(s)-perillic acid	N-[(s) -perilloyl] -D-phenylalanine	44	109-110	$[\alpha]_D^{20} -37.2^\circ$ (C=1, methanol)
23	trans-4-n-propyl-cyclohexane carboxylic acid	N-(trans-4-n-propylcyclohexylcarbonyl)-D-phenylalanine	48	104-105	$[\alpha]_D^{20} -8.8^\circ$ (C=1, methanol)
24	trans-4-n-butyl-cyclohexane carboxylic acid	N-(trans-4-n-butylcyclohexylcarbonyl)-D-phenylalanine	50	144-145	$[\alpha]_D^{20} -7.5^\circ$ (C=1, methanol)
25	4-tert-butylbenzoic acid	N-(4-t-butylbenzoyl)-D-phenylalanine	55	177-178	$[\alpha]_D^{20} +51.5^\circ$ (C=1, methanol)
26	cuminic acid	N-cumoyl-L-phenylalanine	63	121-123	$[\alpha]_D^{23} -29.3^\circ$ (C=1, methanol)
27	cyclopentane carboxylic acid	N-cyclopentylcarbonyl-L-phenylalanine	40	115-117	$[\alpha]_D^{23} +30.1^\circ$ (C=1, methanol)
28	trans-4-methyl-cyclohexane carboxylic acid	N-(trans-4-methylcyclohexylcarbonyl)-D-phenylalanine	43	124-135	$[\alpha]_D^{23} -11.5^\circ$ (C=1, methanol)
29	trans-4-ethyl-cyclohexane carboxylic acid	N-(trans-4-ethylcyclohexylcarbonyl)-D-phenylalanine	53	96-97	$[\alpha]_D^{23} -11.1^\circ$ (C=1, methanol)
30	trans-4-t-butyl-cyclohexane carboxylic acid	N-(trans-4-t-butylcyclohexylcarbonyl)-D-phenylalanine	49	160-161	$[\alpha]_D^{23} -9.0^\circ$ (C=1, methanol)

55 Example 31

N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanine

Platinum oxide (500 mg) as a catalyst was suspended in acetic acid (50 ml) and cumic acid (10 g, 61 mmole) was added thereto. The mixture thus obtained was stirred vigorously for 2 hours at room temperature under a pressure of hydrogen 5 kg/cm². The catalyst was removed by filtration, and the filtrate was concentrated under reduced pressure to a solid state. The resultant substance was distilled under reduced pressure of 1 mmHg (1.3×10^{-3} kg/cm²), at 113-116 °C to obtain 4-isopropylcyclohexane carboxylic acid yielding 10 g (96%) in a ratio of 3 parts of cis-form per 1 part of trans-form by weight.

To methanol (70 ml) at less than -20 °C, thionyl chloride (17 ml) was added dropwise, and the carboxylic acid (10 g) as obtained above was added. The mixture thus obtained was stirred for 15 hours at room temperature, and then concentrated under reduced pressure to a solid substance. The substance thus obtained was distilled under reduced pressure of 0.7 mmHg (9.2×10^{-4} kg/cm²) at 66 °C to obtain 4-isopropylcyclohexane carboxylic acid methyl ester (9.5 g, yield 88%).

To the methyl ester (9.5 g) thus obtained, sodium hydride (120 mg) was added, and the mixture was heated at 150 °C for 2 hours under a current of nitrogen gas. The reaction solution was cooled and then subjected to a reduced pressure distillation of 0.7 mmHg (9.2×10^{-4} kg/cm²) at 66 °C to obtain 4-isopropylcyclohexane carboxylic acid methyl ester in a ratio of 6 parts trans-form per 1 part cis-form.

The methyl ester (9.0 g) thus obtained was dissolved in methanol (50 ml), and 1N aqueous sodium hydroxide solution (50 ml) was added thereto. The mixture thus obtained was stirred for 10 minutes at room temperature and made acidic with an addition of a dilute aqueous hydrochloric acid solution to precipitate crystals. The crystals were filtered, washed with water, and recrystallized from methanol-water to give trans-4-isopropylcyclohexane carboxylic acid (6.8 g, yield 78%).

After that, in the same manner as in Example 21, using as a starting material the carboxylic acid derivative (6.8 g, 40 mmole), N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanine was produced, and recrystallized from methanol-water to give the desired product (8.2 g, yield 65%).
m.p. 129-130 °C

Specific Rotation $[\alpha]_D -9.4^\circ$ (C = 1, methanol)

Examples 32 to 35

In the same manner as in Example 26, using as the starting material the following compounds, each of 40 mmole, the following product compounds were produced.

35

40

45

50

55

5
10
15
20
25
30
35
40
45
50

Example No.	Starting Material	Product	Yield (%)	M.P. (°C)	Specific Rotation
32	trans-4-isopropyl-cyclohexane carboxylic acid	4-(trans-4-isopropyl-cyclohexylcarbonyl)-D-phenylalanine methyl ester	52	137-138	$[\alpha]_D^{20} +8.8^\circ$ (C=1, methanol)
33	trans-4-isopropyl-cyclohexane carboxylic acid	N-(trans-4-isopropyl-cyclohexylcarbonyl)-L-phenylalanine	56	130-131	$[\alpha]_D^{20} +9.5^\circ$ (C=1, methanol)
34	trans-4-isopropyl-cyclohexane carboxylic acid	N-(trans-4-isopropyl-cyclohexylcarbonyl)-2-phenylethylamine	66	134-135	-
35	trans-4-isopropyl-cyclohexane carboxylic acid	N-(trans-4-isopropyl-cyclohexylcarbonyl)-D-phenylalanine benzyl ester	58	129-130.5	$[\alpha]_D^{23} +8.4^\circ$ (C=1, methanol)

55 Example 36

N-(Cis-4-isopropylcyclohexylcarbonyl)-D-phenylalanine

4-Isopropylcyclohexane carboxylic acid methyl ester (9.5 g) (cis-form:trans-form = 3:1) was obtained in the same manner as in Example 26. Cis-4-isopropylcyclohexane carboxylic acid methyl ester (7 g) was obtained from the product thus obtained by a high performance liquid chromatography of YMC A-043 column using as the solvent a mixture of n-hexane and 1,2-dichloro ethane in a ratio of 75:25.

5 After that, in the same manner as in Example 21, using as a starting material the cis-form thus obtained (6.5 g, 38 mmole), N-(cis-4-isopropylcyclohexylcarbonyl)-D-phenyl-alanine was produced, and recrystallized from methanol-water to give the desired product (8 g, yield 66%).

m.p. 111-112°C

Specific Rotation $[\alpha]_D -13.2^\circ$ (C = 1, methanol)

10

Example 37

ICR-CDI mice (Male, five weeks old, Body weight: 20 g) were abstained from food for 18 hours, and then used as test subjects.

15 The phenylalanine derivative of the present invention was suspended in 0.5% CMC-0.14M sodium chloride buffer solution (pH 7.4). The solution thus obtained was administered orally in fixed volume amounts to the test subjects. After a predetermined time, the percentage decrease of the blood glucose against the control group was determined. The results are shown in the following Table.


20

	Example No.	Amounts used of sample mg/kg body weight	Decrease in blood glucose	
				after 60 minutes (%)
25	21	25		26
	22	100		43
	23	"		35
30	24	"		30
	25	"		32
	26	"		0
35	27	"		0
	28	6.25		24
	29	"		31
40	30	"		30
	31	1.5		30
	32	6.25		37
45	33	100		23
	34	"		14
	35	25		24
50	36	100		27

It is clear from the foregoing that the D-phenylalanine derivatives as described above can be used as an anti-diabetic drug for oral administration as well as the more usual parenteral administration.

Claims

1. A D-phenylalanine derivative for pharmaceutical use, represented by the general formula



10 wherein R¹ is selected from hydrogen, alkyl of 1 to 5 carbon atoms, aryl of 6 to 12 carbon atoms, aralkyl of 6 to 12 carbon atoms,



20 -CH₂CO₂R³, -CH(CH₃)-OCO-R³, and -CH₂-OCO-C(CH₃)₃; R² is selected from groups comprising aryl of 6 to 12 carbon atoms, a hetero six-membered ring, a hetero five-membered ring, cycloalkyl, or cycloalkenyl, any of which groups may have one or more substituents; and R³ is selected from hydrogen and alkyl of 1 to 5 carbon atoms, with the proviso that when R¹ and R³ are both hydrogen then R² is other than substituted or unsubstituted phenyl or naphthyl; the salts thereof, and precursors which can be converted thereto in the human or animal body.

25

2. A D-phenylalanine derivative represented by the general formula:



35 wherein R¹ is selected from hydrogen, alkyl of 1 to 5 carbon atoms, aryl of 6 to 12 carbon atoms, aralkyl of 6 to 12 carbon atoms,




45 -CH₂CO₂R³, -CH(CH₃)-OCO-R³, and -CH₂-OCO-C(CH₃)₃; R³ is selected from hydrogen and alkyl of 1 to 5 carbon atoms; and R⁴ is selected from groups comprising phenyl which has one or more alkyl substituents of 2 to 5 carbon atoms, cyclohexyl which has one or more substituents, cyclopentyl, bicycloalkyl, cycloalkenyl, indanyl or 2-benzofuranyl, any of which groups may have one or more substituents, with the proviso that when R¹ and R³ are both hydrogen then R⁴ is other than substituted phenyl or cyclohexyl; the salts thereof, and the precursors which can be converted thereto in the human or animal body.

- 50
3. A derivative of claim 1 or claim 2 wherein R²/R⁴ comprises cyclohexyl, cyclopentyl, 1-cyclohexenyl, 2-cyclohexenyl, 3-cyclohexenyl or 1-cyclopentenyl.
- 55 4. A derivative of any one of claims 1, 2 and 3 wherein said substituent in R²/R⁴, is a halogen atom, alkyl group of 1 to 5 carbon atoms, alkenyl group of 1 to 5 carbon atoms or alkoxy group of 1 to 5 carbon atoms.

5. A derivative of claim 1 or claim 2 wherein R²/R⁴ is cyclohexyl substituted by one or more methylene groups.
6. A derivative of claim 1 or claim 2 wherein:
- 5 R¹ is hydrogen or C₁₋₅ alkyl,
 R³ is hydrogen or C₁₋₅ alkyl; and
 R²/R⁴ is cyclohexyl or cyclohexenyl substituted at the 4- or 5-position by methyl, ethyl, isopropyl, tert-butyl, ethene, or isopropene.
- 10 7. A derivative of claim 6 wherein R¹ is hydrogen and R³ is hydrogen.
8. A derivative of claim 6 or claim 7, wherein R²/R⁴ is perilloyl.
9. A derivative of claim 1 or claim 2 which is N-(4-isopropylcyclohexylcarbonyl)-D-phenylalanine or a salt thereof, or precursor which can be converted thereto in the human or animal body.
- 15 10. A derivative of claim 1 or claim 2 selected from N-(4-isopropylcyclohexylcarbonyl)-D-phenylalanine; N-[(S)-perilloyl]-D-phenylalanine; N-(trans-4-methylcyclohexylcarbonyl)-D-phenylalanine; N-(trans-4-ethylcyclohexylcarbonyl)-D-phenylalanine; N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanine; N-(trans-4-t-butylcyclohexylcarbonyl)-D-phenylalanine; and salts thereof, and precursors which can be converted thereto in the human or animal body.
- 20 11. A derivative of any one of claims 2 to 10 for pharmaceutical use.
- 25 12. A derivative of any one of claims 1 to 10 for use as a hypoglycemic agent.
13. The use of a D-phenylalanine derivative in the preparation of a hypoglycemic medicament, said derivative being represented by the general formula


30



35

wherein R¹ is selected from hydrogen, alkyl of 1 to 5 carbon atoms, aryl of 6 to 12 carbon atoms, aralkyl of 6 to 12 carbon atoms,

40



45


-CH₂CO₂R³, -CH(CH₃)-OCO-R³, and -CH₂-OCO-C(CH₃)₃; R² is selected from groups comprising aryl of 6 to 12 carbon atoms, a hetero six-membered ring, a hetero five-membered ring, cycloalkyl, or cycloalkenyl, any of which groups may have one or more substituents; and R³ is selected from hydrogen and alkyl of 1 to 5 carbon atoms; the salts thereof, and precursors which can be converted thereto in the human or animal body, with the proviso that when R¹ and R³ are both hydrogen and R² is substituted or unsubstituted phenyl or naphthyl, then said derivative is used as the sole therapeutic agent.

14. The use according to claim 13, wherein R² comprises cyclohexyl, cyclopentyl, 1-cyclohexenyl, 2-cyclohexenyl, 3-cyclohexenyl or 1-cyclopentenyl.


15. The use according to claim 13, wherein said substituent in R², is a halogen atom, alkyl group of 1 to 5 carbon atoms, alkenyl group of 1 to 5 carbon atoms or alkoxy group of 1 to 5 carbon atoms.

16. The use according to claim 13, wherein said cyclohexyl group is cyclohexyl substituted by one or more methylene groups.

17. A pharmaceutical composition comprising a D-phenylalanine derivative with a pharmaceutical excipient,
5 said derivative being, represented by the general formula



15 wherein R¹ is selected from hydrogen, alkyl of 1 to 5 carbon atoms, aryl of 6 to 12 carbon atoms, aralkyl of 6 to 12 carbon atoms,



25 -CH₂CO₂R³, -CH(CH₃)-OCO-R³, and -CH₂-OCO-C(CH₃)₃; R² is selected from groups comprising aryl of 6 to 12 carbon atoms, a hetero six-membered ring, a hetero five-membered ring, cycloalkyl, or cycloalkenyl, any of which groups may have one or more substituents; and R³ is selected from hydrogen and alkyl of 1 to 5 carbon atoms; the salts thereof, and precursors which can be converted thereto in the human or animal body, with the proviso that when R¹ and R³ are both hydrogen and R² is substituted or unsubstituted phenyl or naphthyl, then said derivative is the sole therapeutic agent.


30 18. A pharmaceutical composition of claim 17 wherein R² comprises cyclohexyl, cyclopentyl, 1-cyclohexenyl, 2-cyclohexenyl, 3-cyclohexenyl or 1-cyclopentenyl.

19. A pharmaceutical composition of claim 17 wherein said substituent in R² is a halogen atom, alkyl group of 1 to 5 carbon atoms, alkenyl group of 1 to 5 carbon atoms or alkyloxy group of 1 to 5 carbon atoms.


35 20. A pharmaceutical composition of claim 17 wherein said cyclohexyl group is cyclohexyl substituted by one or more methylene groups.

Revendications

40 1. Un dérivé de la D-phénylalanine pour utilisation pharmaceutique, représenté par la formule générale :



50 dans laquelle R' est choisi parmi d'hydrogène, un groupe alkyle de 1 à 5 atomes de carbone, un groupe aryle de 6 à 12 atomes de carbone, un groupe aralkyle de 6 à 12 atomes de carbone,




-CH₂CO₂R³, -CH(CH₃)-OCO-R³, et -CH₂-OCO-C(CH₃)₃; R² est choisi dans le groupe comprenant un groupe aryle de 6 à 12 atomes de carbone, un noyau hétérocyclique à 6 chaînons, un noyau cycloalkyle, ou cycloalcényle, ces groupes pouvant avoir un ou plusieurs substituants; et R³ est choisi parmi l'hydrogène et un groupe alkyle de 1 à 5 atomes de carbone, à la condition que, lorsque R¹ et R³ sont tous les deux de l'hydrogène, alors R² a une définition autre que le groupe phényle ou naphtyle substitué ou non substitué; les sels dudit dérivé et les précurseurs qui peuvent être convertis en ce dérivé dans le corps de l'homme ou de l'animal.

2. Un dérivé de la D-phénylalanine représenté par la formule générale :

10


15



dans laquelle R¹ est choisi parmi l'hydrogène, un groupe alkyle de 1 à 5 atomes de carbone, un groupe aryle de 6 à 12 atomes de carbone, un groupe aralkyle de 6 à 12 atomes de carbone,

20

25



-CH₂CO₂R³, -CH(CH₃)-OCO-R³ et -CH₂-OCO-C(CH₃)₃; R³ est choisi parmi l'hydrogène et un radical alkyle de 1 à 5 atomes de carbone; et R⁴ est choisi parmi les groupes comprenant le groupe phényle qui comporte un ou plusieurs substituants alkyles de 2 à 5 atomes de carbone, un groupe cyclohexyle qui a un ou plusieurs substituants, un groupe cyclopentyle, bicycloalkyle, cycloalcényle, indanyl ou 2-benzofurannyle, chacun de ces groupes pouvant avoir un ou plusieurs substituants, à la condition que, lorsque R¹ et R³ sont tous les deux de l'hydrogène, alors R⁴ a une signification autre que le groupe phényle ou cyclohexyle substitué; les sels dudit dérivé et les précurseurs qui peuvent être convertis en ledit dérivé dans le corps humain ou animal.

3. Un dérivé selon la revendication 1 ou 2, dans lequel R²/R⁴ désigne un groupe cyclohexyle, cyclopentyle, 1-cyclohexényle, 2-cyclohexényle, 3-cyclohexényle ou 1-cyclopentényle.
- 40 4. Un dérivé selon l'une quelconque des revendications 1, 2 et 3, selon lequel ledit substituant dans R²/R⁴ est un atome d'halogène, un groupe alkyle de 1 à 5 atomes de carbone, un groupe alcényle de 1 à 5 atomes de carbone ou un groupe alkyloxy de 1 à 5 atomes de carbone.
- 45 5. Un dérivé selon la revendication 1 ou 2, selon lequel R²/R⁴ est un groupe cyclohexyle substitué par un ou plusieurs groupes méthylènes.
6. Un dérivé selon la revendication 1 ou 2, selon lequel
- 50 R¹ est l'hydrogène ou un groupe C₁₋₅ alkyle,
R³ est un hydrogène ou un groupe C₁₋₅ alkyle, et
R²/R⁴ est un groupe cyclohexyle ou cyclohexényle substitué dans la position 4- ou 5- par un groupe méthyle, éthyle, isopropyle, tert-butyle, éthène ou isopropène.
7. Un dérivé selon la revendication 6, selon lequel R¹ est l'hydrogène et R³ est l'hydrogène.
- 55 8. Un dérivé selon la revendication 6 ou 7, selon lequel R²/R⁴ est le groupe périlloyle.
9. Un dérivé selon la revendication 1 ou 2, qui est la N-(4-isopropylcyclohexylcarbonyl)-D-phénylalanine

ou un sel de cette dernière, ou un précurseur qui peut être converti en cette dernière dans le corps humain ou animal.


10. Un dérivé selon la revendication 1 ou 2, choisi parmi les suivants : N-(4-isopropylcyclohexylcarbonyl)-D-phénylalanine ; N-[*(S*)-perrilloyl]-D-phénylalanine ; N-(trans-4-méthylcyclohexylcarbonyl)-D-phénylalanine ; N-(trans-4-éthylcyclohexylcarbonyl)-D-phénylalanine ; N-(trans-4-isopropylcyclohexylcarbonyl)-D-phénylalanine ; N-(trans-4-t-butylcyclohexylcarbonyl)-D-phénylalanine ; et leurs sels et leurs précurseurs qui peuvent être convertis en ces composés dans le corps humain ou animal.

11. Un dérivé selon l'une quelconque des revendications 2 à 10 pour l'utilisation pharmaceutique.

12. Un dérivé selon l'une quelconque des revendications 1 à 10 à utiliser comme agent hypoglycémiant.


13. Utilisation d'un dérivé de la D-phénylalanine dans la préparation d'un médicament hypoglycémiant, ledit dérivé étant représenté par la formule générale :

20



dans laquelle R¹ est choisi parmi l'hydrogène, un groupe alkyle de 1 à 5 atomes de carbone, un groupe aryle de 6 à 12 atomes de carbone, un groupe aralkyle de 6 à 12 atomes de carbone,

30




35 -CH₂CO₂R³, -CH(CH₃)-OCO-R³ et -CH₂-OCO-C(CH₃)₃ ; R² est choisi parmi les groupes comprenant un groupe aryle de 6 à 12 atomes de carbone, un noyau hétérocyclique à 6 chaînons, un noyau hétérocyclique à 5 chaînons, un groupe cycloalkyle, ou cycloalcényle, chacun de ces groupes pouvant avoir un ou plusieurs substituants ; et R³ est choisi parmi l'hydrogène et un groupe alkyle de 1 à 5 atomes de carbone ; les sels dudit dérivé et les précurseurs qui peuvent être convertis en ce dérivé dans le corps humain ou animal, à la condition que, lorsque R¹ et R³ sont tous les deux de l'hydrogène et R² est un groupe phényle ou naphtyle substitué ou non substitué, alors ledit dérivé est utilisé comme seul agent thérapeutique.

40 14. Utilisation selon la revendication 13, selon laquelle R² désigne un groupe cyclohexyle, cyclopentyle, 1-cyclohexényle, 2-cyclohexényle, 3-cyclohexényle ou 1-cyclopentényle.

45 15. Utilisation selon la revendication 13, selon laquelle ledit substituant dans R² est un atome d'halogène, un groupe alkyle de 1 à 5 atomes de carbone, un groupe alcényle de 1 à 5 atomes de carbone ou un groupe alkyloxy de 1 à 5 atomes de carbone.


50 16. Utilisation selon la revendication 13, selon laquelle ledit groupe cyclohexyle est un groupe cyclohexyle substitué par un ou plusieurs groupes méthylènes.

55 17. Une composition pharmaceutique comprenant un dérivé de la D-phénylalanine avec un excipient pharmaceutique, ledit dérivé étant représenté par la formule générale :



dans laquelle R¹ est choisi parmi l'hydrogène, un groupe alkyle de 1 à 5 atomes de carbone, un groupe aryle de 6 à 12 atomes de carbone, un groupe aralkyle de 6 à 12 atomes de carbone,

10




-CH₂CO₂R³, -CH(CH₃)-OCO-R³ et -CH₂-OCO-C(CH₃)₃; R² est choisi parmi les groupes comprenant un groupe aryle de 6 à 12 atomes de carbone, un noyau hétérocyclique à 6 chaînons, un noyau hétérocyclique à 5 chaînons, un groupe cycloalkyle ou un groupe cycloalcényle, chacun desdits groupes pouvant avoir un ou plusieurs substituants; et R³ est choisi parmi l'hydrogène et un groupe alkyle de 1 à 5 atomes de carbone; les sels dudit dérivé et les précurseurs qui peuvent être convertis en ce dérivé dans le corps humain ou animal, à la condition que, lorsque R¹ et R³ sont tous les deux de l'hydrogène et R² est un groupe phényle ou naphtylé substitué ou non substitué, alors ledit dérivé est le seul agent thérapeutique.

- 20
18. Une composition pharmaceutique selon la revendication 17, selon laquelle R² désigne un groupe cyclohexyle, cyclopentyle, 1-cyclohexényle, 2-cyclohexényle, 3-cyclohexényle ou 1-cyclopentényle.
- 30
19. Une composition pharmaceutique selon la revendication 17, selon laquelle ledit substituant dans R² est un atome d'halogène, un groupe alkyle de 1 à y atomes de carbone, un groupe alcényle de 1 à 5 atomes de carbone ou un groupe alkyloxy de 1 à 5 atomes de carbone.
- 35
20. Une composition pharmaceutique selon la revendication 17, selon laquelle ledit groupe cyclohexyle est un groupe cyclohexyle substitué par un ou plusieurs groupes méthylènes.


Patentansprüche

- 40 1. D-Phenylalaninderivat zur pharmazeutischen Verwendung, repräsentiert durch die allgemeine Formel



worin R¹ aus Wasserstoff, Alkyl mit 1 bis 5 Kohlenstoffatomen, Aryl mit 6 bis 12 Kohlenstoffatomen, Aralkyl mit 6 bis 12 Kohlenstoffatomen,

55




-CH₂CO₂R³, -CH(CH₃)-OCO-R³ und -CH₂-OCO-C(CH₃)₃ ausgewählt ist; R² aus den aus Aryl mit 6 bis

12 Kohlenstoffatomen, einem sechsgliedrigen Heteroring, einem fünfgliedrigen Heteroring, Cycloalkyl oder Cycloalkenyl bestehenden Gruppen ausgewählt ist, wobei jede dieser Gruppen einen oder mehrere Substituenten aufweisen kann; und R³ aus Wasserstoff und Alkyl mit 1 bis 5 Kohlenstoffatomen ausgewählt ist, mit der Maßgabe, daß, wenn R¹ und R³ beide Wasserstoff sind, R² nicht substituiertes oder unsubstituiertes Phenyl oder Naphthyl ist; seine Salze sowie Vorläufer, die im menschlichen oder tierischen Körper in das Derivat umgewandelt werden können.

2. D-Phenylalaninderivat der allgemeinen Formel


10



15

worin R¹ aus Wasserstoff, Alkyl mit 1 bis 5 Kohlenstoffatomen, Aryl mit 6 bis 12 Kohlenstoffatomen, Aralkyl mit 6 bis 12 Kohlenstoffatomen,

20



25

-CH₂CO₂R³, -CH(CH₃)-OCO-R³ und -CH₂-OCO-C(CH₃)₃ ausgewählt ist; R³ aus Wasserstoff und Alkyl mit 1 bis 5 Kohlenstoffatomen ausgewählt ist und R⁴ aus Phenyl das einen oder mehrere Alkylsubstituenten mit 2 bis 5 Kohlenstoffatomen hat, Cyclohexyl mit einem oder mehreren Substituenten, Cyclopentyl, Bicycloalkyl, Cycloalkenyl, Indanyl oder 2-Benzofuranyl ausgewählt ist, wobei jede dieser Gruppen einen oder mehrere Substituenten aufweisen kann, mit der Maßgabe, daß, wenn R¹ und R³ beide Wasserstoff sind, R⁴ nicht substituiertes Phenyl oder Cyclohexyl ist; seine Salze sowie Vorläufer, die im menschlichen oder tierischen Körper in das Derivat umgewandelt werden können.

35

3. Derivat nach Anspruch 1 oder Anspruch 2, worin R²/R⁴ Cyclohexyl, Cyclopentyl, 1-Cyclohexenyl, 2-Cyclohexenyl, 3-Cyclohexenyl oder 1-Cyclopentenyl umfaßt.

4. Derivat nach einem der Ansprüche 1, 2 und 3, worin der Substituent in R²/R⁴ ein Halogenatom, eine Alkylgruppe mit 1 bis 5 Kohlenstoffatomen, eine Alkenylgruppe mit 1 bis 5 Kohlenstoffatomen oder eine Alkoxygruppe mit 1 bis 5 Kohlenstoffatomen ist.

40

5. Derivat nach Anspruch 1 oder Anspruch 2, worin R²/R⁴ durch eine oder mehrere Methylengruppen substituiertes Cyclohexyl ist.

6. Derivat nach Anspruch 1 oder Anspruch 2, worin:

45

R¹ Wasserstoff oder C₁-5-Alkyl,

R³ Wasserstoff oder C₁-5-Alkyl und

R²/R⁴ Cyclohexyl oder Cyclohexenyl ist, die in 4- oder 5-Stellung durch Methyl, Ether, Isopropyl, t-Butyl, Ethen oder Isopropan substituiert sind.

50

7. Derivat nach Anspruch 6, worin R¹ Wasserstoff und R³ Wasserstoff ist.

8. Derivat nach Anspruch 6 oder Anspruch 7, worin R²/R⁴ Perillyl ist.


55

9. Derivat nach Anspruch 1 oder Anspruch 2, das N-(4-Isopropylcyclohexylcarbonyl)-D-phenylalanin oder ein Salz davon oder ein Vorläufer ist, der im menschlichen oder tierischen Körper in dieses umgewandelt werden kann.


10. Derivat nach Anspruch 1 oder Anspruch 2, ausgewählt aus N-(4-Isopropylcyclohexylcarbonyl)-D-

phenylalanin; N-[(S)-Perillyl]-D-phenylalanin; N-trans-4-Methylcyclohexylcarbonyl-D-phenylalanin; N-(trans-4-Ethylcyclohexylcarbonyl)-D-phenylalanin; N-trans-4-Isopropylcyclohexylcarbonyl)-D-phenylalanin; N-(trans-4-t-Butylcyclohexylcarbonyl)-D-phenylalanin; und seinen Salzen sowie Vorläufern, die im menschlichen oder tierischen Körper in das Derivat umgewandelt werden können.

- 5 11. Derivat nach einem der Ansprüche 2 bis 10 zur pharmazeutischen Verwendung.
 12. Derivat nach einem der Ansprüche 1 bis 10 zur Verwendung als hypoglykämisches Mittel.
 10 13. Verwendung eines D-Phenylalaninderivats bei der Herstellung eines hypoglykämischen Arzneimittels, wobei das Derivat durch die allgemeine Formel




20 repräsentiert wird, in der R¹ aus Wasserstoff, Alkyl mit 1 bis 5 Kohlenstoffatomen, Aryl mit 6 bis 12 Kohlenstoffatomen, Aralkyl mit 6 bis 12 Kohlenstoffatomen,



30 -CH₂CO₂R³, -CH(CH₃)-OCO-R³ und -CH₂-OCO-C(CH₃)₃ ausgewählt ist; R² aus den aus Aryl mit 6 bis 12 Kohlenstoffatomen, einem sechsgliedrigen Heteroring, einem fünfgliedrigen Heteroring, Cycloalkyl oder Cycloalkenyl bestehenden Gruppen ausgewählt ist, wobei jede dieser Gruppen einen oder mehrere Substituenten aufweisen kann; und R³ aus Wasserstoff und Alkyl mit 1 bis 5 Kohlenstoffatomen ausgewählt ist; seinen Salzen sowie Vorläufern, die im menschlichen oder tierischen Körper in das Derivat umgewandelt werden können, mit der Maßgabe, daß, wenn R¹ und R³ beide Wasserstoff sind und R² substituiertes oder unsubstituiertes Phenyl oder Naphthyl ist, das Derivat als das einzige therapeutische Mittel verwendet wird.


- 35
 40 14. Verwendung nach Anspruch 13, wobei R² Cyclohexyl, Cyclopentyl, 1-Cyclohexenyl, 2-Cyclohexenyl, 3-Cyclohexenyl oder 1-Cyclopentenyl umfaßt.
 15. Verwendung nach Anspruch 13, wobei der Substituent in R² ein Halogenatom, eine Alkylgruppe mit 1 bis 5 Kohlenstoffatomen, eine Alkenylgruppe mit 1 bis 5 Kohlenstoffatomen oder eine Alkoxygruppe mit 1 bis 5 Kohlenstoffatomen ist.
 45 16. Verwendung nach Anspruch 13, wobei die Cyclohexylgruppe eine durch eine oder mehrere Methylengruppen substituierte Cyclohexylgruppe ist.
 17. Pharmazeutische Zusammensetzung, die ein D-Phenylalaninderivat mit einem pharmazeutischen Träger enthält, wobei das Derivat durch die allgemeine Formel



55 repräsentiert wird, in der R¹ aus Wasserstoff, Alkyl mit 1 bis 5 Kohlenstoffatomen, Aryl mit 6 bis 12

Kohlenstoffatomen, Aralkyl mit 6 bis 12 Kohlenstoffatomen,

5



-CH₂CO₂R³, -CH(CH₃)-OCO-R³ und -CH₂-OCO-C(CH₃)₃ ausgewählt ist; R² aus den aus Aryl mit 6 bis 10 Kohlenstoffatomen, einem sechsgliedrigen Heteroring, einem fünfgliedrigen Heteroring, Cycloalkyl oder Cycloalkenyl bestehenden Gruppen ausgewählt ist, wobei jede dieser Gruppen einen oder mehrere Substituenten aufweisen kann; und R³ aus Wasserstoff und Alkyl mit 1 bis 5 Kohlenstoffatomen ausgewählt ist; seine Salze sowie Vorläufer, die im menschlichen oder tierischen Körper in das Derivat umgewandelt werden können, mit der Maßgabe, daß, wenn R¹ und R³ beide Wasserstoff sind und R² substituiertes oder unsubstituiertes Phenyl oder Naphthyl ist, das Derivat das einzige therapeutische Mittel ist.

18. Pharmazeutische Zusammensetzung nach Anspruch 17, worin R² Cyclohexyl, Cyclopentyl, 1-Cyclohexenyl, 2-Cyclohexenyl, 3-Cyclohexenyl oder 1-Cyclopentenyl umfaßt.
19. Pharmazeutische Zusammensetzung nach Anspruch 17, worin der Substituent in R² ein Halogenatom, eine Alkylgruppe mit 1 bis 5 Kohlenstoffatomen, eine Alkenylgruppe mit 1 bis 5 Kohlenstoffatomen oder eine Alkyloxygruppe mit 1 bis 5 Kohlenstoffatomen ist.
20. Pharmazeutische Zusammensetzung nach Anspruch 17, worin die Cyclohexylgruppe eine durch eine oder mehrere Methylengruppen substituierte Cyclohexylgruppe ist.

30

35

40

45

50

55